Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate. IDEFIRIX sales amounted to SEK61m. The communication from the FDA about a potential priority review this month will be an important share catalyst.
LÄS MER
